Selected research
Industry Research
DNA Gyrase Subunit B (EC 5.99.1.3) Industry Research Report 2026
Market perspective
The global DNA Gyrase Subunit B (EC 5.99.1.3) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the DNA Gyrase Subunit B (EC 5.99.1.3) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the DNA Gyrase Subunit B (EC 5.99.1.3) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the DNA Gyrase Subunit B (EC 5.99.1.3) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of DNA Gyrase Subunit B (EC 5.99.1.3) include Merck & Co., Inc., AstraZeneca Plc, Daiichi Sankyo Company Ltd and Abgentis Limited, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global DNA Gyrase Subunit B (EC 5.99.1.3) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to DNA Gyrase Subunit B (EC 5.99.1.3).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
DNA Gyrase Subunit B (EC 5.99.1.3) Market by Company
Merck & Co., Inc.
AstraZeneca Plc
Daiichi Sankyo Company Ltd
Abgentis Limited
DNA Gyrase Subunit B (EC 5.99.1.3) Segment by Type
VXC-100
VT-12008911
GYR-12
DS-2969
Others
DNA Gyrase Subunit B (EC 5.99.1.3) Segment by Application
Bacterial Infections
Clostridium Diffclie Infections
Klebsiella Pneumoniae Infections
Others
DNA Gyrase Subunit B (EC 5.99.1.3) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA Gyrase Subunit B (EC 5.99.1.3) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DNA Gyrase Subunit B (EC 5.99.1.3) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA Gyrase Subunit B (EC 5.99.1.3).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of DNA Gyrase Subunit B (EC 5.99.1.3) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- VXC-100
- VT-12008911
- GYR-12
- DS-2969
- Others
Applications
- Bacterial Infections
- Clostridium Diffclie Infections
- Klebsiella Pneumoniae Infections
- Others
Companies covered
- Merck & Co., Inc.
- AstraZeneca Plc
- Daiichi Sankyo Company Ltd
- Abgentis Limited
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 DNA Gyrase Subunit B (EC 5.99.1.3) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 VXC-100
- 2.2.3 VT-12008911
- 2.2.4 GYR-12
- 2.2.5 DS-2969
- 2.2.6 Others
- 2.3 DNA Gyrase Subunit B (EC 5.99.1.3) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Bacterial Infections
- 2.3.3 Clostridium Diffclie Infections
- 2.3.4 Klebsiella Pneumoniae Infections
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 DNA Gyrase Subunit B (EC 5.99.1.3) Breakdown Data by Type
- 3.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Historic Market Size by Type (2021-2026)
- 3.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Forecasted Market Size by Type (2027-2032)
4 DNA Gyrase Subunit B (EC 5.99.1.3) Breakdown Data by Application
- 4.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Historic Market Size by Application (2021-2026)
- 4.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Perspective (2021-2032)
- 5.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Growth Trends by Region
- 5.2.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 DNA Gyrase Subunit B (EC 5.99.1.3) Historic Market Size by Region (2021-2026)
- 5.2.3 DNA Gyrase Subunit B (EC 5.99.1.3) Forecasted Market Size by Region (2027-2032)
- 5.3 DNA Gyrase Subunit B (EC 5.99.1.3) Market Dynamics
- 5.3.1 DNA Gyrase Subunit B (EC 5.99.1.3) Industry Trends
- 5.3.2 DNA Gyrase Subunit B (EC 5.99.1.3) Market Drivers
- 5.3.3 DNA Gyrase Subunit B (EC 5.99.1.3) Market Challenges
- 5.3.4 DNA Gyrase Subunit B (EC 5.99.1.3) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top DNA Gyrase Subunit B (EC 5.99.1.3) Players by Revenue
- 6.1.1 Global Top DNA Gyrase Subunit B (EC 5.99.1.3) Players by Revenue (2021-2026)
- 6.1.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue Market Share by Players (2021-2026)
- 6.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of DNA Gyrase Subunit B (EC 5.99.1.3) Head Office and Area Served
- 6.4 Global DNA Gyrase Subunit B (EC 5.99.1.3) Players, Product Type & Application
- 6.5 Global DNA Gyrase Subunit B (EC 5.99.1.3) Manufacturers Established Date
- 6.6 Global DNA Gyrase Subunit B (EC 5.99.1.3) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (2021-2032)
- 7.2 North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2021-2026)
- 7.4 North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (2021-2032)
- 8.2 Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2021-2026)
- 8.4 Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (2021-2032)
- 9.2 Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (2021-2032)
- 10.2 South America DNA Gyrase Subunit B (EC 5.99.1.3) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2021-2026)
- 10.4 South America DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (2021-2032)
- 11.2 Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck & Co., Inc.
- 12.1.1 Merck & Co., Inc. Company Information
- 12.1.2 Merck & Co., Inc. Business Overview
- 12.1.3 Merck & Co., Inc. Revenue in DNA Gyrase Subunit B (EC 5.99.1.3) Business (2021-2026)
- 12.1.4 Merck & Co., Inc. DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
- 12.1.5 Merck & Co., Inc. Recent Developments
- 12.2 AstraZeneca Plc
- 12.2.1 AstraZeneca Plc Company Information
- 12.2.2 AstraZeneca Plc Business Overview
- 12.2.3 AstraZeneca Plc Revenue in DNA Gyrase Subunit B (EC 5.99.1.3) Business (2021-2026)
- 12.2.4 AstraZeneca Plc DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
- 12.2.5 AstraZeneca Plc Recent Developments
- 12.3 Daiichi Sankyo Company Ltd
- 12.3.1 Daiichi Sankyo Company Ltd Company Information
- 12.3.2 Daiichi Sankyo Company Ltd Business Overview
- 12.3.3 Daiichi Sankyo Company Ltd Revenue in DNA Gyrase Subunit B (EC 5.99.1.3) Business (2021-2026)
- 12.3.4 Daiichi Sankyo Company Ltd DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
- 12.3.5 Daiichi Sankyo Company Ltd Recent Developments
- 12.4 Abgentis Limited
- 12.4.1 Abgentis Limited Company Information
- 12.4.2 Abgentis Limited Business Overview
- 12.4.3 Abgentis Limited Revenue in DNA Gyrase Subunit B (EC 5.99.1.3) Business (2021-2026)
- 12.4.4 Abgentis Limited DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
- 12.4.5 Abgentis Limited Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst